New device aims to zap away atrial fibrillation
NCT ID NCT05115214
First seen Feb 19, 2026 · Last updated Jun 23, 2026 · Updated 15 times
Summary
This study tests a new catheter system called SpherePVI that uses heat to destroy tiny areas of heart tissue causing atrial fibrillation (an irregular heartbeat). About 150 people with symptomatic atrial fibrillation will undergo the procedure. The goal is to see if the device can safely and effectively restore a normal heart rhythm.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Homolka Hospital
RECRUITINGPrague, Czechia
Contact
-
Institute Klinicke a Experimentalni Mediciny
RECRUITINGPrague, Czechia
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SpherePVI™ catheter (a device that uses heat energy to destroy small areas of heart tissue causing irregular heartbeat)
What this could lead to
If successful, this could provide a safer, more effective way to treat atrial fibrillation and help patients maintain a normal heart rhythm without long-term medication.
What could go wrong
This is an early-stage study with only 150 participants, so results may not apply to everyone. There are risks like stroke, heart damage, or bleeding from the procedure.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.